Any feedback?
Literature summary for 3.4.21.9 extracted from
- Overexpression and refolding of thioredoxin/TRAIL fusion from inclusion bodies and further purification of TRAIL after cleavage by enteropeptidase (2007), Biotechnol. Lett., 29, 1567-1573.
Application
| Application | Comment | Organism |
|---|---|---|
| medicine | human TRAIL is a candidate for clinical application in cancer therapy, activity is lost in some forms of recombinant TRAIL, refolding of thioredoxin/TRAIL and cleavage by enteropeptidase yield a biological active anticancer agent | Homo sapiens |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Homo sapiens | - |
- |
- |
Substrates and Products (Substrate)
| Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
|---|---|---|---|---|---|---|
| thioredoxin-tumor necrosis factor-related apoptosis-inducing ligand fusion protein + H2O | trx/TRAIL | Homo sapiens | thioredoxin + tumor necrosis factor-related apoptosis-inducing ligand | enteropeptidase is used to cleave TRAIL from thioredoxin at enzyme-substrate molar ratio of 1 : 30,000 | ? |  |
Synonyms
| Synonyms | Comment | Organism |
|---|---|---|
| enteropeptidase | - |
Homo sapiens |
| enteropeptidase light chain | L-HEP | Homo sapiens |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
